Creating a world without ALS, together
Currently, less than 5% of patients participate in clinical trials. TRICALS aims to open clinical trials to all people with ALS – giving them and their loved ones the chance to make a meaningful contribution to ridding the world of ALS, forever.
The direct involvement of people with ALS is essential and urgent. Each person with ALS holds an important piece of the puzzle, and putting the puzzle together will help us to find new and more effective treatments. We believe that with our new approach, where we all work together, we can make the difference. We can turn ALS into a condition that is treatable. When we all work together, we can build a highway towards a cure.
We aren’t looking for one single solution as we know that ALS is complex and every patient is different. Therefore it’s important to find precise treatments that suit the different forms of ALS that we’ve grown to understand through work such as our own Project MinE.
During Project Mine, we collected tens of thousands of DNA profiles, and realized that each patient holds a piece of the puzzle within themselves. This is why TRICALS collects and combines patient data. Based on the different types of ALS people have, clinical trial design can be expanded and improved, targeted more precisely, and carried out more quickly.
We have made significant progress in our understanding of ALS although this has been unacceptably slow and there remains much more to learn. We believe that with our new approach when we all work together, miracles can happen, including a cure
Why TRICALS will make a difference
TRICALS is the worlds largest network of trained specialised ALS centres. The very best experts from top research centres around the globe have teamed up with patients’ organisations, fundraisers and pharma companies in a unique international collaboration to find a cure for ALS
large trained specialised ALS centres
new patients each year
The very best experts from top research centres around the globe have teamed up with patients’ organisations, fundraisers and pharma companies in a unique international collaboration to find a cure for ALS.